- Home
- DCGO vs ABOS Comparison
DCGO vs ABOS Comparison
Compare DCGO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCGO | ABOS |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 113.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DCGO | ABOS |
|---|---|---|
| Price | $0.88 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.33 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 663.4K | 168.8K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $368,093,385.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $0.86 |
| 52 Week High | $5.68 | $2.46 |
Technical Indicators
Market Signals| Indicator | DCGO | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 63.63 |
| Support Level | $0.88 | $2.01 |
| Resistance Level | $0.99 | $2.15 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 1.12 | 79.37 |
Price Performance
Historical ComparisonAbout DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.